Clinical manifestations and long-term symptoms associated with SARS-CoV-2 omicron infection in children aged 0–17 years in Beijing: a single-center study

Jing Li, Jingjing Li, Ling Cao, Lin Wang, Xiaobo Chen, Wenquan Niu, Li Dang, Shuzhi Dai, Ying Wang, Menglei Ge, Weijie Liu, Qinwei Song, Wenjian Xu, Lijuan Ma
{"title":"Clinical manifestations and long-term symptoms associated with SARS-CoV-2 omicron infection in children aged 0–17 years in Beijing: a single-center study","authors":"Jing Li, Jingjing Li, Ling Cao, Lin Wang, Xiaobo Chen, Wenquan Niu, Li Dang, Shuzhi Dai, Ying Wang, Menglei Ge, Weijie Liu, Qinwei Song, Wenjian Xu, Lijuan Ma","doi":"10.3389/fped.2024.1332020","DOIUrl":null,"url":null,"abstract":"The study aims to analyze the clinical characteristics of acute phase of SARS-CoV-2 infection in children aged 0–17 years with the Omicron variant, and summarize the persistent symptoms or new-onset clinical manifestations from 4 to 12 weeks after acute COVID. Explore the association between the vaccination status and SARS-CoV-2 neutralizing antibody levels post infection among preschool-aged children. The comprehensive study systematically describes the clinical characteristics of children infected with SARS-CoV-2, providing a foundation for diagnosis and evaluating long-term COVID in pediatric populations.The study enrolled children who were referred to the Children's Hospital, Capital Institute of Pediatrics, (Beijing, China) from January 10, 2023 to March 31, 2023. Participants were classified as infant and toddlers, preschool, school-age, and adolescent groups. Children or their legal guardians completed survey questionnaires to provide information of previous SARS-CoV-2 infection history, as well as clinical presentation during the acute phase and long-term symptoms from 4 to 12 weeks following infection. Furthermore, serum samples were collected from children with confirmed history of SARS-CoV-2 infection for serological testing of neutralizing antibodies.The study recruited a total of 2,001 children aged 0–17 years who had previously tested positive for SARS-CoV-2 through nucleic acid or antigen testing. Fever emerged as the predominant clinical manifestation in 1,902 (95.1%) individuals with body temperature ranging from 37.3 to 40.0°C. Respiratory symptoms were identified as secondary clinical manifestations, with cough being the most common symptom in 777 (38.8%) children, followed by sore throat (22.1%), nasal congestion (17.8%), and runnning nose (17.2%). Fatigue (21.6%), headache (19.8%) and muscle-joint pain (13.5%) were frequently reported systemic symptoms in children. The proportion of children with symptoms of SARS-CoV-2 infection varied across age groups. 1,100 (55.0%) children experienced persistent symptoms from 4 to 12 weeks post the acute phase of infection. Trouble concentrating (22.1%), cough (22.1%), and fatigue (12.1%) were frequently reported across age groups in the extended period. A limited number of children exhibited cardiovascular symptoms with chest tightness, tachycardia, and chest pain reported by 3.5%, 2.5%, and 1.8% of children, respectively. Among 472 children aged 3–5 years, 208 children had received two doses of SARS-CoV-2 vaccine at least 6 months prior to infection, and no association was found between the incidence of long-term COVID and pre-infection vaccination statuses among the 3–5 years age groups (χ2 = 1.136, P = 0.286).In children aged 0–17 years infected with SARS-CoV-2 Omicron variant, fever was the primary clinical manifestation in the acute phase, followed by respiratory symptoms, systemic non-specific and digestive presentations. In particular, respiratory and digestive system symptoms were more frequent in children aged above 6 years. Regarding the long-term symptoms from 4 to 12 weeks post-infection, the most common presentations were concentrating difficulty, cough, and fatigue. The incidence of persistent symptoms of SARS-CoV-2 did not exhibit a significant correlation with vaccination status, which was attributed to the waning efficacy of the vaccine-induced humoral immune response after 6 months.","PeriodicalId":510143,"journal":{"name":"Frontiers in Pediatrics","volume":"53 22","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pediatrics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fped.2024.1332020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The study aims to analyze the clinical characteristics of acute phase of SARS-CoV-2 infection in children aged 0–17 years with the Omicron variant, and summarize the persistent symptoms or new-onset clinical manifestations from 4 to 12 weeks after acute COVID. Explore the association between the vaccination status and SARS-CoV-2 neutralizing antibody levels post infection among preschool-aged children. The comprehensive study systematically describes the clinical characteristics of children infected with SARS-CoV-2, providing a foundation for diagnosis and evaluating long-term COVID in pediatric populations.The study enrolled children who were referred to the Children's Hospital, Capital Institute of Pediatrics, (Beijing, China) from January 10, 2023 to March 31, 2023. Participants were classified as infant and toddlers, preschool, school-age, and adolescent groups. Children or their legal guardians completed survey questionnaires to provide information of previous SARS-CoV-2 infection history, as well as clinical presentation during the acute phase and long-term symptoms from 4 to 12 weeks following infection. Furthermore, serum samples were collected from children with confirmed history of SARS-CoV-2 infection for serological testing of neutralizing antibodies.The study recruited a total of 2,001 children aged 0–17 years who had previously tested positive for SARS-CoV-2 through nucleic acid or antigen testing. Fever emerged as the predominant clinical manifestation in 1,902 (95.1%) individuals with body temperature ranging from 37.3 to 40.0°C. Respiratory symptoms were identified as secondary clinical manifestations, with cough being the most common symptom in 777 (38.8%) children, followed by sore throat (22.1%), nasal congestion (17.8%), and runnning nose (17.2%). Fatigue (21.6%), headache (19.8%) and muscle-joint pain (13.5%) were frequently reported systemic symptoms in children. The proportion of children with symptoms of SARS-CoV-2 infection varied across age groups. 1,100 (55.0%) children experienced persistent symptoms from 4 to 12 weeks post the acute phase of infection. Trouble concentrating (22.1%), cough (22.1%), and fatigue (12.1%) were frequently reported across age groups in the extended period. A limited number of children exhibited cardiovascular symptoms with chest tightness, tachycardia, and chest pain reported by 3.5%, 2.5%, and 1.8% of children, respectively. Among 472 children aged 3–5 years, 208 children had received two doses of SARS-CoV-2 vaccine at least 6 months prior to infection, and no association was found between the incidence of long-term COVID and pre-infection vaccination statuses among the 3–5 years age groups (χ2 = 1.136, P = 0.286).In children aged 0–17 years infected with SARS-CoV-2 Omicron variant, fever was the primary clinical manifestation in the acute phase, followed by respiratory symptoms, systemic non-specific and digestive presentations. In particular, respiratory and digestive system symptoms were more frequent in children aged above 6 years. Regarding the long-term symptoms from 4 to 12 weeks post-infection, the most common presentations were concentrating difficulty, cough, and fatigue. The incidence of persistent symptoms of SARS-CoV-2 did not exhibit a significant correlation with vaccination status, which was attributed to the waning efficacy of the vaccine-induced humoral immune response after 6 months.
北京 0-17 岁儿童感染 SARS-CoV-2 omicron 后的临床表现和长期症状:一项单中心研究
本研究旨在分析 0-17 岁儿童感染 SARS-CoV-2 奥米克龙变异型后急性期的临床特征,并总结急性 COVID 后 4 至 12 周的持续症状或新发临床表现。探讨学龄前儿童接种疫苗情况与感染后 SARS-CoV-2 中和抗体水平之间的关联。这项综合研究系统地描述了感染SARS-CoV-2的儿童的临床特征,为诊断和评估儿科人群的长期COVID奠定了基础。研究对象分为婴幼儿组、学龄前组、学龄期组和青少年组。患儿或其法定监护人填写调查问卷,提供既往SARS-CoV-2感染史、急性期临床表现以及感染后4至12周的长期症状等信息。研究共招募了 2,001 名 0-17 岁的儿童,这些儿童曾通过核酸或抗原检测对 SARS-CoV-2 呈阳性反应。1,902人(95.1%)的主要临床表现为发热,体温在37.3至40.0°C之间。呼吸道症状是次要临床表现,777 名儿童(38.8%)最常见的症状是咳嗽,其次是喉咙痛(22.1%)、鼻塞(17.8%)和流鼻涕(17.2%)。疲劳(21.6%)、头痛(19.8%)和肌肉关节痛(13.5%)是儿童经常报告的全身症状。不同年龄组别的儿童中出现 SARS-CoV-2 感染症状的比例各不相同。1,100名儿童(55.0%)在感染急性期后的4至12周内出现持续症状。在延长期,各年龄组中经常出现注意力不集中(22.1%)、咳嗽(22.1%)和疲劳(12.1%)等症状。少数儿童表现出心血管症状,分别有3.5%、2.5%和1.8%的儿童出现胸闷、心动过速和胸痛。在 472 名 3-5 岁儿童中,有 208 名儿童在感染前至少 6 个月接种过两剂 SARS-CoV-2 疫苗,在 3-5 岁年龄组中,长期 COVID 的发生率与感染前接种疫苗的情况之间没有关联(χ2 = 1.136,P = 0.286)。其中,呼吸系统和消化系统症状在 6 岁以上儿童中更为常见。至于感染后 4 至 12 周的长期症状,最常见的表现是注意力难以集中、咳嗽和疲劳。SARS-CoV-2 持续症状的发生率与疫苗接种情况无明显相关性,这是因为疫苗诱导的体液免疫反应的效力在 6 个月后逐渐减弱。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信